Synchron secures $200m to advance Stentrode platform commercialisation

Synchron Secures $200M to Propel Stentrode Platform Commercialisation

US-based Synchron has raised $200 million in a Series D funding round to advance the commercial launch of its Stentrode brain-computer interface (BCI) platform and support the development of next-generation interfaces.

Funding Round and Investors

The investment round was led by Double Point Ventures and backed by ARCH Ventures, Bezos Expeditions, Khosla Ventures, METIS, and NTI. New investors joining this round include the Australian National Reconstruction Fund (NRF), Qatar Investment Authority (QIA), T.Rx Capital, K5 Global, IQT, and Protocol Labs.

Use of Funds

Statement from Synchron CEO

“We’ve built the first non-surgical brain-computer interface designed for everyday life for people with paralysis. This funding brings us closer to commercialising the Stentrode BCI platform, while accelerating development of a major breakthrough in the field – a next-generation, transcatheter high-channel whole-brain interface.” – Tom Oxley, Founder and CEO

Synchron aims to combine innovation with practical application to improve the lives of those affected by paralysis.

Additional Notes

Synchron combines business intelligence and editorial expertise to reach professionals across multiple media platforms, ensuring informed and proactive decision-making in response to evolving policies.

Author’s summary: Synchron’s $200 million funding milestone marks a significant step forward in commercialising a pioneering non-surgical brain-computer interface to enhance life for people with paralysis.

more

Medical Device Network Medical Device Network — 2025-11-07

More News